4Dominique D. Oncological application of FDG PET imaging : brain tumors, colorectal cancer lymphoma and melanoma. J Nucl Med, 1999, 40: 591-603.
5Jerusalem G, Paulus P, Warland V, et al. Whole body positron emission tomography using 18F-fluorodeoxyglucose in the staging of Hodgkin disease and non-Hodgkin lymphoma. Eur J Nucl Med, 1995, 22: 786-795.
6Hob CK, Glaspy J, Rosen P, et al. Whole body FDG PET imaging for staging of Hodgkin disease and lympboma. J Nucl Med, 1997, 38: 343-348.
7Bares R, Horstman K, Altehoefer C, et al. ^18F-FDG PET to assess local effect of radiation or chemotherapy in patients with malignant lymphoma. J Nucl Med, 1991, 27: 56-58.
8Ell PJ. PET/CT in oncology: a major technology for cancer care. Chang Gung Med J, 2005, 28: 274-283.
9Rodriguez-Catanno M, Jerkeman M, Ahlstrom H, et al. Residual mass in aggressive lymphoma-does size, measured by computed tomography, influence clinical outcome? Acta Oncol, 2000, 39:485-489.
10Van Den Berg H, Verhulst L, Behrendt H, et al. Persistent mediastinal mass is not Indicative of recurrence after chemotherapy only in paediatric Hodgkins disease. Br J Haematol, 2000, 109: 104-108.
